Last updated: 2026-09-20 22:21:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Obsidian Therapeutics, Inc. (OBX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.68, with a market capitalisation of $1.10B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.57 to $49.97. This page covers its latest market performance, valuation, price trends and company information.
$1.10B | |
$17.61 | |
$49.97 | |
$14.57 | |
$17.50 | |
469.64K | |
370.04K | |
-- | |
$49.97 | |
$14.57 | |
-- | |
-- |
Obsidian Therapeutics, Inc. (OBX) last closed at $17.50 as of 2026-09-18 23:31:00, unchanged from the previous close of $17.50.
During the latest regular trading session, OBX traded between $14.57 and $49.97, with a volume of 469.64K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Obsidian Therapeutics, Inc. (OBX) moved from $17.16 to $17.68, representing a gain of 3.04% ($0.52).
The stock traded between $16.91 and $19.55 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 1.11 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.8%
OBX is currently trading at $17.68, placing it 8.8% of the way from its 52-week low of $14.57 to its 52-week high of $49.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Obsidian Therapeutics, Inc. (OBX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.